Breaking News

Statement by US Secretary of Labor Walsh on November Jobs Report B-21 Raider makes public debut; will become backbone of Air Force’s bomber fleet > Air Force > Article Display Africa-U.S.: Commercial Ties will Shape the Partnership in the 21st Century Readout of Secretary Raimondo’s Meeting with Mexican Secretary of Economy Raquel Buenrostro Readout of Secretary Raimondo’s Meeting with French Minister of the Economy, Finance, and Industrial and Digital Sovereignty Bruno Le Maire US Department of Labor finds Family Dollar Stores again exposing workers to fire, entrapment, struck-by hazards, this time at Richmond Hill location The 91st Annual California State Capitol Tree Lighting Ceremony Heightened Financing, Women and Youth Participation Vital for Peace Efforts, Speakers Tell Economic and Social Council, Peacebuilding Commission

Issued:  Friday 23 January 2009, London UK

GlaxoSmithKline plc (GSK) today announced that it has signed an agreement with UCB S.A to acquire its current marketed product portfolio across certain territories in Africa, the Middle East, Asia Pacific and Latin America, for a cash consideration of €515 million (£483 million.)

Commenting on the acquisition Abbas Hussain, President, Emerging Markets, GSK said, “As part of our strategy to grow and diversify GSK’s business, we are continuing to make new investments in emerging markets. This acquisition will strengthen and expand GSK’s product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory.”

As a result of the agreement, GSK will acquire several leading pharmaceutical brands in a number of disease areas. These include Keppra® for the treatment of epilepsy and Xyzal® and Zyrtec® for the treatment of allergic rhinitis. 

The commercial operations and product distribution rights to be acquired by GSK represent approximately three to four percent of UCB’s 2008 expected revenue of at least €3.3 billion (£3.09 billion.)

The acquired products will be sold in multiple territories.  Asia Pacific territories include Malaysia, Taiwan, Thailand and Vietnam.  Middle Eastern territories include Egypt, Pakistan, Saudi Arabia and United Arab Emirates.  African territories include South Africa.  Latina territories include Argentina and Chile.  Territories excluded are China, South Korea, India, Australia, Mexico, Brazil and Malta.

Completion of the acquisition is expected to take place in late March 2009.

Notes to editors

This acquisition follows the agreement GSK announced with South African-based pharmaceuticals company Aspen in July 2008, which significantly extended GSK’s pharmaceuticals portfolio in emerging markets, the acquisition of the Egyptian mature products business of Bristol Myers Squibb (BMS) in October 2008 and the acquisition of BMS Pakistan in December 2008.

Emerging markets are forecast to account for 40% of growth in the worldwide pharmaceutical market by 2020. GSK already has a strong geographical footprint in emerging markets and has established a new strategy to accelerate sales growth in these markets, through broadening its product portfolio.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit



UK Media enquiries:

Philip Thomson

(020) 8047 5502


Alice Hunt

(020) 8047 5502


David Outhwaite

(020) 8047 5502


Stephen Rea

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Sarah Alspach

(215) 751 7709



European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill

(215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2007.

Source link